fda warning letters glp-1 october 2025 news issued 30 to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's September crackdown on misleading The FDA sent a warning

Your weight loss journey should be safe, informed, and personalized

Without adequate protein, lean muscle tissue may be broken down alongside fat

ADAs 2026 Standards are expanding the relevance of GLP-1-based therapies in diabetes, obesity, and related metabolic care

Emerging evidence suggests that allulose may exert GLP-1-like effects through multiple pathways: Incretin hormone stimulation : Studies demonstrate that allulose consumption stimulates the release of GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) from intestinal L-cells and K-cells, respectively

(J Diabetes Invest, doi: 10 cells by the incretin hormone glucosedependent insulinotropic polypeptide